Vyepti denied by insurance? Appeal and win.
A denial of Vyepti is not the end of the road. It is the opening move in a process that is frequently overturned on appeal. Most denials come down to two things the plan wants to see and that the original request did not fully document: proof that the right oral preventive medications or preferred CGRP agents were already tried, and a clear paper trail showing your migraine frequency and treatment response. When those gaps are filled, and the request is mapped to the plan's own coverage criteria, these decisions often reverse.
Reviewed by the Apellica Appeals Team · Updated June 2026
Carrier names and logos are trademarks of their respective owners. Apellica is independent and not affiliated with any insurance carrier or carrier's appeal program.
Vyepti (eptinezumab) is FDA approved for the preventive treatment of migraine in adults. It is used for both episodic migraine and chronic migraine to reduce the number of monthly migraine days. It is the first intravenous preventive migraine therapy, given as an infusion once every three months at a dose of 100 mg, with some patients benefiting from 300 mg. It works by binding to calcitonin gene-related peptide, or CGRP, a protein involved in triggering migraine attacks.
Why Vyepti gets denied
- Step therapy not satisfied: the plan requires documented trial and failure of a set number of oral preventive medications (such as topiramate, beta-blockers, or amitriptyline) before covering a CGRP agent.
- Non-formulary or non-preferred status: the plan prefers a self-injected CGRP antibody (such as Aimovig, Ajovy, or Emgality) and wants that tried first before approving an IV agent like Vyepti.
- Prior authorization criteria not documented: the request did not include the migraine diagnosis, monthly migraine day count, or prior treatment history the plan requires.
- Site-of-care restriction: because Vyepti is an IV infusion, the plan denies a hospital outpatient setting and redirects to a lower-cost site such as a physician's office, infusion center, or home infusion.
What a winning appeal includes
- A confirmed migraine diagnosis with the correct ICD-10 code (for example G43.709 for chronic migraine without aura, not intractable, or G43.009 for migraine without aura), plus documented monthly migraine and headache day counts establishing episodic or chronic migraine.
- A complete record of prior preventive therapies tried, the dates, the doses, and why each was stopped, whether for inadequate response, intolerable side effects, or contraindication.
- A point-by-point letter of medical necessity that maps the patient's history directly to each element of the plan's written coverage criteria.
- Documentation of treatment response or expected benefit, such as a headache diary or reduction in monthly migraine days, which is also the standard the plan applies for continuation of therapy.
How we approach the appeal
First identify which type of denial you received, because the path differs. If the drug is non-formulary or on a disfavored tier, file a formulary or tier exception arguing that preferred alternatives are inappropriate or have failed. If the denial is a prior authorization or medical necessity decision, appeal by quoting the plan's own criteria back to it, line by line, with matching documentation for each requirement. Where the plan demands prior oral preventive failures, cite the American Headache Society position that CGRP-targeting therapies are appropriate first-line options for migraine prevention, and document any failures or contraindications that already satisfy the rule.
Vyepti appeal letter template
Copy this Vyepti appeal letter, fill in the brackets, and send it within your deadline. It is built on what overturns CGRP inhibitor (anti-CGRP monoclonal antibody) denials.
[Date] [Your name] · Member ID [ID] · Rx claim # [#] [Insurer or PBM] - Appeals Department Re: Appeal of Vyepti denial I am appealing the denial of Vyepti (eptinezumab). I request that the denial be overturned and Vyepti approved. 1. The denial. [Insurer] denied Vyepti stating, verbatim: "[paste the exact denial reason from your letter]." 2. Medical necessity. Vyepti is medically necessary for my condition. First identify which type of denial you received, because the path differs. If the drug is non-formulary or on a disfavored tier, file a formulary or tier exception arguing that preferred alternatives are inappropriate or have failed. If the denial is a prior authorization or medical necessity decision, appeal by quoting the plan's own criteria back to it, line by line, with matching documentation for each requirement. Where the plan demands prior oral preventive failures, cite the American Headache Society position that CGRP-targeting therapies are appropriate first-line options for migraine prevention, and document any failures or contraindications that already satisfy the rule. 3. Step-therapy or formulary exception (if that was the reason): I have tried and failed [preferred drug(s)], with pharmacy records attached, or the preferred alternative is contraindicated because [reason]. I request a formulary or step-therapy exception. 4. My request. Approve Vyepti within the timeframe required by law. If the denial is upheld, please provide the specific criteria used, the reviewing clinician's credentials, and external-review instructions. Attached: prescriber letter of medical necessity, pharmacy and prior-trial records, and supporting clinical notes. Sincerely, [Your name]
Want it built and filed for you? Use the free generator, or have Apellica do it.
Internal appeals: 30 days pre-service, 60 days post-service, 72 hours urgent. File within 180 days of the denial.
$0 upfront. We assess fit first, then build and file the appeal for you.
- · The denial letter and your Explanation of Benefits (EOB)
- · Insurance ID, plan name, and the claim or prior-authorization number
- · Diagnosis with ICD-10 code and the prescriber's clinical notes
- · A record of treatments already tried and how they worked
Appealing a Vyepti denial by insurer
The path depends on who manages your benefit. The most common:
Coverage runs through the pharmacy benefit. Appeal the coverage determination and, when the drug is non-formulary, file a formulary or tier exception with a provider attestation that covered alternatives are unsuitable.
Publishes detailed prior-authorization criteria. A denial usually means a criterion was not documented. Appeal through a coverage review, with a formulary exception for excluded drugs.
Administers many UnitedHealthcare and employer plans. Appeals and exceptions follow the plan's published PA criteria; expedited review exists for urgent cases.
Internal appeal first, then independent external review. Pre-service decisions are generally made within 30 days, urgent within 72 hours.
Internal appeals and external review; pharmacy denials often route through OptumRx criteria.
Independent state plans, so criteria vary. Match the appeal to your specific BCBS plan, internal appeal first, then external review.
Frequently asked questions
My plan says I have to fail two oral preventive pills before Vyepti. I already tried some years ago. Does that count?
It can, if it is documented. Pull your pharmacy and visit records showing the medication name, dose, dates, and the reason you stopped, whether it was lack of benefit or side effects. Past trials that meet the plan's step therapy rule should be submitted in your appeal, even if they happened with a prior doctor. If you also had a contraindication to a required drug, that usually satisfies the requirement without an actual trial.
The insurer approved Vyepti but denied getting it at the hospital. Can I appeal where I receive the infusion?
Yes. Because Vyepti is an IV infusion, many plans apply a separate site-of-care policy that steers infusions to a lower-cost setting such as a physician's office, a standalone infusion center, or home infusion. If your clinical situation requires a specific setting, your physician can document that need and appeal the site-of-care decision specifically, which is separate from the drug approval itself.
My insurer covers Aimovig and Emgality but denied Vyepti. Why, and can I still get Vyepti?
Plans often prefer the self-injected CGRP antibodies first because they are less expensive to administer than an IV infusion. To win Vyepti, your appeal should explain why the preferred self-injected options are not appropriate, for example a documented failure, an intolerance, an adherence barrier, or a clinical reason the every-three-month IV route is preferred. Mapping that rationale to the plan's exception criteria is what flips these denials.
Vyepti denied? We fight it for you.
$0 upfront. Two-minute intake. We confirm fit and reply within one business day with the right path for your situation.
Start Your AppealThis page provides general information about appeal strategy. It is not legal or medical advice. Apellica is not a law firm. Outcomes depend on documentation, plan terms, and timing.